You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Dovato

Product menu

DOVATO IS NOW BEING ASSESSED IN TREATMENT-NAÏVE PATIENTS IN THE REAL WORLD

Looking at the larger treatment naïve studies (effectiveness outcomes with >30 patients) we can see Dovato has low rates of virological failure with a consistent high barrier to resistance4-10

RWE Tx Naive Summary Graphic used on Dovato Vx

DTG 50 mg + 3TC 300 mg used in most reported real-world studies.

This bar graph for real-world evidence shows the high virological effectiveness of DOVATO across 6 of the real-world studies.

DTG 50 mg + 3TC 300 mg used in most reported real-world studies.
*Virological effectiveness was 85.2% in the intent-to-treat–exposed analysis.
†Loss of suppression defined as 2 consecutive HIV-1 viral loads ≥200 copies/mL in individuals who have initially achieved virological suppression; blips defined as HIV-1 viral loads >50 copies/mL after initially achieved virological suppression.

TOLERABILITY YOU EXPECT FROM DTG + 3TC IN REAL-WORLD STUDIES

Studies Reporting Discontinuations Due to AEs With ≥20 Patients (n=3/10)

RWE Tx Naive Tolerability Graph used in Viiv Exchange

AE=adverse event.
DTG 50 mg + 3TC 300 mg used in most reported real-world studies.
Percentage calculated based on overall N on DOVATO as the denominator.

SWITCH TO DOVATO: GROWING REAL-WORLD DATA CONTINUE TO REINFORCE ROBUST EFFICACY

Looking at the larger treatment experienced studies (effectiveness outcomes with >250 patients) we can see dovato has low rates of virological failure with a consistent high barrier to resistance8,10,15,19

Real-World Evidence Baseline Characteristics Switch Patients

DTG 50 mg + 3TC 300 mg used in most reported real-world studies.

This bar graph for real-world evidence shows the high virological effectiveness of DOVATO across 6 of the real-world studies.

DTG 50 mg + 3TC 300 mg used in most reported real-world studies.
*18 virological rebound events (calculation assumes ≤1 virological rebound event per patient).
†Virological failure defined as confirmed viral load >50 copies/mL or one single viral load >200 copies/mL.
‡Loss of suppression defined as 2 consecutive HIV-1 viral loads ≥200 copies/mL in individuals who have initially achieved virological suppression; blips defined as HIV-1 viral load >50 copies/mL after initially achieved virological suppression.
§Confirmed virological failure defined as 2 viral loads ≥200 copies/mL or discontinuation after 1 viral load ≥200 copies/mL.

TOLERABILITY YOU EXPECT FROM DTG + 3TC IN REAL-WORLD STUDIES

Studies Reporting Discontinuations Due to AEs With ≥100 Patients (n=4/16)

Real-World Evidence Switch Tolerability

AE=adverse event.
DTG 50 mg + 3TC 300 mg used in most reported real-world studies.
Percentage calculated based on overall N on DOVATO as the denominator.

Bar chart

The efficacy of DOVATO has been proven in clinical trials

See the Data

Shield

Real-world evidence also confirms the high barrier to resistance of DOVATO

Explore the High Barrier to Resistance

References:

  1. Montaner JS, Wood E, Kerr T et al. Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes. J Acquir Immune Defic Syndro. 2010;55 Suppl. 1:5
  2. Eisinger RW, Dieffenbach CW, Fauci AS. HIV VIral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable. JAMA. 2019;321(5):451-452.
  3. Pierone G, Fusco JS, Brunet L, et al. Suppressed switch to DTG/3TC 2-drug regimen vs. BIC- or DTG-based 3-drug regimens. Presented at: IDWeek 2022; October 19-23, 2022; Washington, DC, USA. Poster.
  4. Cabello A, López Bernaldo de Quiros JC, Pulido F, et al. 48 weeks efficacy and tolerability of dolutegravir (DTG) + lamivudine (3TC) in adult HIV naïve patients: a multicenter real life cohort. Presented at: The 11th International AIDS Society Conference on HIV Science; July 18-21, 2021; Virtual.
  5. Calza L, Legnani G, Fulgaro C, et al. Changes in serum inflammatory markers in antiretroviral therapy-naïve HIV-infected patients starting dolutegravir/lamivudine or dolutegravir/lamivudine/abacavir. J Acquir Immune Defic Syndr. 2022;89(3):e30. doi:10.1097/QAI.0000000000002861
  6. Dou Y, Li Y, Hong Z, et al. The efficacy of DTG+3TC in naïve HIV patients—the real world data from southern China. Presented at: 18th European AIDS Conference; October 27-30, 2021; London, England. Poster PE2/19.
  7. Hidalgo-Tenorio C, Pasquau J, Vinuesa D, et al. DOLAVI real-life study of dolutegravir plus lamivudine in naïve HIV-1 patients (48 weeks). Viruses. 2022;14(3):524. doi:10.3390/v14030524
  8. Nasreddine R, Yombi JC, Darcis G, et al. Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium. Presented at: 11th edition of the AFRAVIH Conference; April 6-9, 2022. Marseille, France. Oral CO4.1.
  9. Schneider S, Burke C, Ward D, et al. Treatment experience of single-tablet dolutegravir/lamivudine in the United States: results from the ‘real-world outcomes with dolutegravir-based two-drug-regimens Dovato and Juluca for the treatment of HIV-1' (TANDEM study). Presented at: The 24th International AIDS Conference; July 29-August 2, 2022; Montreal, Canada. Poster EPB147.
  10. Scholten S, Noe S, Wyen C, et al. 12-month outcomes of dolutegravir (DTG) + lamivudine (3TC) in ART-naïve and pre-treated people living with HIV in Germany: real-world data from the German URBAN cohort. Presented at: 18th European AIDS Conference; October 27-30, 2021; London, England. Poster PE2/52.
  11. Ciccullo A, Baldin G, Dusina A, et al. Short communication: efficacy and safety of dolutegravir plus lamivudine as a first-line regimen in clinical practice. AIDS Res Hum Retroviruses. 2021;37(6):486-488. doi:10.1089/AID.2020.0276
  12. Gianotti N, Tavell A, Antinori A, et al. Are patients starting first-line ART with a 2-drug regimen (2DR) with dolutegravir/lamivudine different from those initiating 3-drug regimens (3DR) based on an integrase strand transfer inhibitor (InSTI), plus tenofovir alafenamide/emtricitabine. Presented at: The 11th IAS Conference on HIV Science; July 18-21, 2021. Poster A-IAS2021-00429.
  13. Stephenson L, Pan D. Clinical experience of dolutegravir + lamivudine dual treatment regimens at University Hospital Leicester NHS Trust. Presented at: 26th Annual Conference of the British HIV Association; November 22-24, 2020; Virtual.
  14. Mendoza I, Lázaro A, Torralba M. Effectiveness, durability, and safety of dolutegravir and lamivudine versus dolutegravir, lamivudine, and abacavir in a real-life cohort of HIV-infected adults. Annal of Pharm. 2022;56(4):412-421. doi:10.1177/10600280211034176
  15. Bravo O, Martínez-Alfaro E, Galera C, et al. Multi-central study to evaluate effectiveness and safety of the dolutegravir and lamivudine biterapy in vida real. Presented at: Grupo de Estudio del Sida-Seimc; December 10-13, 2019; Toledo, Spain. Abstract P-145.
  16. Gagliardini R, Lorenzini P, Cozzi-Lepri A, et al; for the Icona Foundation Study Group. Effect of past virological failure on dolutegravir + lamivudine as maintenance regimen. Presented at: Conference on Retroviruses and Opportunistic Infections; March 8-11, 2020; Boston, MA. Poster 0486.
  17. Hocqueloux L, Allavena C, Sécher S, et al. Archived mutation M184V does not increase virologic failure during maintenance therapy with dolutegravir + lamivudine in the French DAT’AIDS cohort. Presented at: 18th European AIDS Conference; October 27-30, 2021; London, England. Oral Session OS1-2.
  18. Krentz HB, Campbell S, Lahl M, Gill MJ. Uptake success and cost savings from switching to a two-drug antiretroviral regimen. AIDS Patient Care STDS. 2022;36(1):1-7. doi:10.1089/apc.2021.0118
  19. Pierone G, Brunet L, Fusco JS, et al. Switching to dolutegravir/lamivudine two-drug regimen: durability and virologic outcomes in routine U.S. clinical care. Presented at: The 24th International AIDS Conference; July 29-August 2, 2022; Montreal, Canada. Poster.
  20. Amor García MA, Rodríguez-González CG, Chamorro-de-Vega E, Herranz-Alonso A, Sanjurjo-Sáez M. Dolutegravir-based dual therapies in HIV pretreated patients: a real-life study in Madrid. Ann Pharmacother. 2022;56(4):401-411. doi:10.1177/10600280211038504
  21. Calza L, Colangeli V, Borderi M, et al. Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy. J Antimicrob Chemother. 2020;75(11):3327-3333. doi:10.1093/jac/dkaa319
  22. Maggiolo F, Gulminetti R, Pagnucco L, et al. Five years durability of dolutegravir + lamivudine in patients with suppressed HIV-RNA. Presented at: The 11th International AIDS Society Conference on HIV Science; July 18-21, 2021; Virtual.
  23. Tan M, Johnston S, Nicholls J, Gompels M. Dual therapy with renally adjusted lamivudine and dolutegravir: a switch strategy to manage comorbidity and toxicity in older, suppressed patients? HIV Medicine. 2019;20(9):634-637. doi:10.1111/hiv.12781
  24. Uriel AJ, Banks T, Ashton K, et al. Dual antiretroviral (ARV) therapy: safe and efficacious even in a heavily ARV experienced real-world cohort. Presented at: 26th Annual Conference of the British HIV Association; November 22-24, 2020; Virtual.
  25. Yagci-Caglayik D, Gokengin D, Inan A, et al. Real life experience of dolutegravir and lamivudine dual therapy as a switching regimen in HIVTR cohort. Presented at: The 16th European AIDS conference; October 25-27, 2017. Milan, Italy.
  26. Haidari G, Barchi W, Chilton D, Kulasegaram R. Dolutegravir/lamivudine (DTG/3TC) in people living with HIV (PLWH) as a switch or start: a London based experience. Presented at: The 18th European AIDS conference, October 27-30th, 2021. London, United Kingdom.
  27. Bowman C, Ambrose A, Simons P, et al. Performance of dolutegravir based two drug regimens (DTG-2DR) in a large real-world cohort of people with HIV. Presented at: The British HIV Association Spring Conference 2022; April 20-22, 2022. Manchester, United Kingdom. Poster.
  28. Hiryak K, Kludjian G, Samuel R, et al. Real-world implementation of dolutegravir-lamivudine to achieve and maintain HIV-1 viral suppression at an academic medical center. Presented at: ID Week; October 21-25, 2020; Virtual.
  29. Ma J, Nance RM, Delaney JAC, et al. Current antiretroviral treatment among people with HIV in the US: findings from the CNICS cohort. J Clin Inf Dis. 2022;1-15. doi:10.1093/cid/ciac086
  30. Alves Correia RM, Carvalho AC. Real life study with dual therapy in a HIV-1 treatment experienced Portuguese Cohort. Presented at: The 23rd International AIDS Conference; July 6-10, 2020. Virtual. Poster PEB0235.
  31. Cucchetto G, Lanzafame M, Nicolé S, et al. Integrase inhibitors with lamivudine, as maintenance-dual therapy, in a real-life clinical settings. Presented at: The Italian Conference on AIDS and Retroviruses, June 6-8 2016, Milan, Italy. P69.
  32. Pasqua Liaño J, Sequera Arquelladas S, López-Cortez, et al. DOLAM study 200: effectiveness safety and economic evaluation of a dual therapy with dolutegravir plus lamivudine in treatment-experienced HIV patients. Presented at: The 18th European AIDS conference, October 27-30th, 2021. London, United Kingdom. Poster PE2-38.
  33. Fernández Zamora C, Rodriguez Martinez T, Merono Saura MA, et al. Effectiveness of dolutegravir and lamivudine therapy in a two drug regimen in a third level hospital. Eur J Hosp Pharm. 2020;27(suppl 1):A79. doi:10.1136/ejhpharm-2020-eahpconf.169
  34. Santoro MM, Armenia D, Teyssou E, et al. Impact of M184V on the virological efficacy of switch to 3TC/DTG in real life. Presented at: CROI 2021. Poster.
  35. Lanzafame M, Nicole S, Rizzardo S, et al. Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1 infected patients deintensificated from abacavir/lamivudine/dolutegravir to lamivudine plus dolutegravir. New Microbiol. 2018;41(4):262-267.
  36. Malagnino V, Teti E, Compagno M, et al. HBcAb positivity is a risk factor for an increased detectability of HIV RNA after switching to a two-drug regimen lamivudine-based (2DR-3TC-based) treatment: analysis of a multicenter Italian cohort. Microorganisms. 2021;9(2):396. doi:10.3390/microorganisms9020396
  37. Ciccullo A, Borghi V, Giacomelli A, et al. Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding. J Acquir Immune Defic Syndr. 2021;88(3):234-237. doi:10.1097/QAI.0000000000002787
  38. Pereira Goulart S, de Albuquerque Moras C, Furtado da Costa A, et al. ART simplification: use of dual therapy for HIV in a public health reference center (CRT-DST/Aids) in São Paulo, Brazil. Presented at: 17th European AIDS Conference; November 6-9, 2019; Basel, Switzerland. Poster PE2/34.
  39. Rodríguez Alonso B, Úbeda C, Bonilla M, et al. P203 efficacy and tolerance of dolutegravir-based bitherapy (DTG) in simplification outside clinical trials. Presented at: GeSIDA 2017. Poster P203.
  40. Teira R, Diaz-Cuervo H, Aragão F, et al. Shorter time to treatment failure in people living with HIV switched to dolutegravir plus either rilpivirine or lamivudine compared to integrase inhibitor-based triple therapy in a large Spanish cohort (VACH). Presented at: 26th Annual Conference of the British HIV Association; November 22-24, 2020; Virtual. Poster P031.
  41. Vergas TJ, Estrada J, Perez-Somarriba J, et al. P-190. Bitherapies without protease inhibitors. a safe and efficient option. Presented at: GeSIDA 2017.
  42. Silva Sombra, Loiola MM, Vasconcelo M, et al. Simplification with lamivudine/dolutegravir dual therapy in HIV patients with real-life virological suppression (LAMDO study). Braz J Infect Dis. 2021;25:(S1). Abstract.
  43. Ruiz-Algueró M, Hernando V, Riero M, et al. Temporal trends and geographic variability in the prescription of antiretroviral treatments in people living with HIV in Spain, 2004-2020. J Clin Med. 2022;11(7):1896. doi:10.3390/jcm11071896

Dovato is a registered trade mark of the ViiV Healthcare group of companies or its licensor.

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Date of Preparation: January 2025
PM-IE-DLL-WCNT-240002